Peptide Drug

DRAVP ID	Name	Description	Disease	Pubchem ID
DRAVPc031	Maftivimab(REGN-3479)	Maftivimab is part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.Maftivimab is indicated in combination with Odesivimab and Atoltivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions.INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.	Zaire ebolavirus infection	381609201
DRAVPc032	Odesivimab(REGN-3471)	Odesivimab is part of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells. Odesivimab is indicated in combination with Maftivimab and Atoltivimab for the treatment of Zaire ebolavirus infection in adult and pediatric patients, including neonates born to a mother who has been confirmed positive by RT-PCR for Zaire ebolavirus infection. INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Maftivimab (REGN 3479), Odesivimab (REGN 3471), and Atoltivimab (REGN 3470) in equimolar proportions.INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.	Zaire ebolavirus infection	381608746
DRAVPc033	Ansuvimab	Ansuvimab is a fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease. Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.	Zaire ebolavirus infection	433770931
DRAVPc034	Leronlimab(PRO 140)	Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.4 It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.	HIV infection, COVID-19	135308456
DRAVPc035	Ibalizumab	Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes.This drug was approved in March 2018 for the management of treatment-resistant HIV, in October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.	HIV infection	347911363
DRAVPc036	Gimsilumab(MORAB-022)	Gimsilumab is under investigation in clinical trial and used for COVID-19.	COVID-19	381127889
DRAVPc037	Gontivimab(ALX0171)	Gontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).	Respiratory Syncytial Virus Lower Respiratory Tract Infection	402425649
DRAVPc038	Ansuvimab	Ansuvimab, formerly mAb114, is a fully human IgG1 mAb derived from a survivor of the 1995 Kikwit EBOV outbreak 11 years after infection, which displays strong glycan-independent binding to a conserved region of the GP1,2 protein that is responsible for interacting with the host NPC1 protein to mediate EBOV endolysosomal escape, a key step in the EBOV lifecycle. Ansuvimab received FDA approval on December 21, 2020, and is currently marketed as Ebanga by Ridgeback Biotherapeutics, LP. Ansuvimab is just the second FDA-approved treatment for EVD.	Zaire ebolavirus infection	433770931
DRAVPc039	Astegolimab	Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).	COVID-19	402425721
DRAVPc040	Zansecimab	Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19). It is a humanized IgG4 isotype antibody that neutralizes phospho-Tie2 induction due to Ang2, thereby stopping angiogenesis. The mechanism behind the neutralization is due to the antibody binding with high affinity to, and inhibiting Ang2.	COVID-19	434370480